The Epstein–Barr virus small capsid protein BFRF3 disrupts the NF‐кB signaling pathway by inhibiting p65 activity
The FASEB Journal · 2024
DOI: 10.1096/fj.202400952r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Meili Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Affiliated Hospital of Guangzhou Medical University; The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical Univ…. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Capsid Proteins, Transcription Factor RelA, Signal Transduction. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), Natural Science Foundation of Guangdong Province (Guangdong Basic and Applied Basic Research Foundation).
Abstract (Originalsprache)
Epstein–Barr virus (EBV), a common gamma herpesvirus, establishes a life‐long latent infection in the host to defend against innate immune recognition, which is closely related to a variety of malignant tumors, but its specific mechanism is unclear. BFRF3, an EBV‐encoded small capsid protein, is mainly involved in the assembly of the viral capsid structure and the maintenance of its stability. Here, we showed that BFRF3 can inhibit TNF‐α‐mediated NF‐кB promoter activation. Moreover, BFRF3 downregulates NF‐кB‐mediated promoter activation and transcription of inflammatory cytokines, including IL‐6 and IL‐8. Dual‐luciferase reporter assay demonstrated that BFRF3 restrains NF‐кB promoter activity at or below the p65 level, and coimmunoprecipitation analysis revealed that BFRF3 not only interacts with p65 but also binds to its critical truncated Rel homology domain (RHD) and transcriptional activation domain (TAD). However, BFRF3 does not affect the dimerization of p65‐p50, but overexpression of BFRF3 reduces the nuclear accumulation of p65, and the phosphorylation of p65 (Ser536) is repressed during BFRF3 transfection and EBV lytic infection, which promotes the proliferation of EBV. Overall, our study suggested that BFRF3 may play a crucial role in antiviral immunity to defend against EBV infection by inhibiting NF‐κB activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth Affiliated Hospital of Guangzhou Medical University; The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University; State Key Laboratory of Respiratory Disease, Guangdong Provinc…
- The Affiliated Panyu Central Hospital, of Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Pathogenic Biology and Immunology, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.
- Department of Laboratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
- School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, Guangdong, China.
- State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Meili Li
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | National Natural Science Foundation of China (NSFC)
- Natural Science Foundation of Guangdong Province (Guangdong Basic and Applied Basic Research Foundation)
- Specialized Areas Project for General Universities of Guangdong Province (Biomedicine and Health)
- China Postdoctoral Science Foundation: 2024M750644; Open Project of State Key Laboratory of Respiratory Disease
- Science and Technology Project in Key Fields of Nansha District
- Open Research Funds from the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
- Guangzhou Medical University Discipline Construction Funds (Basic Medicine)
Zitieren
APA
Li, M., Li, Y., Liu, Y., Li, X., Lao, S., Long, Z., Huang, C., Huang, W., Xu, C., Chen, X., Adam, F. E. A., Zhang, G., Li, L., Zhang, J., Peng, T., Su, M., Chen, S., Hou, S., Xiao, B., & Cai, M. (2024). The Epstein–Barr virus small capsid protein BFRF3 disrupts the NF‐кB signaling pathway by inhibiting p65 activity. The FASEB Journal. https://doi.org/10.1096/fj.202400952r
Vancouver
Li M, Li Y, Liu Y, Li X, Lao S, Long Z, et al. The Epstein–Barr virus small capsid protein BFRF3 disrupts the NF‐кB signaling pathway by inhibiting p65 activity. The FASEB Journal. 2024. doi:10.1096/fj.202400952r
BibTeX
@article{Li2024,
author = {Li, Meili and Li, Yiwen and Liu, Yintao and Li, Xiaoqing and Lao, Shuxian and Long, Zhiwei and Huang, Chen and Huang, Wenzhuo and Xu, Chunyan and Chen, Xinru and Adam, Fathalrhman Eisa Addoma and Zhang, Guirong and Li, Linhai and Zhang, Jian and Peng, Tao and Su, Meiting and Chen, Shengwen and Hou, Shaozhen and Xiao, Bin and Cai, Mingsheng},
title = {The Epstein–Barr virus small capsid protein BFRF3 disrupts the NF‐кB signaling pathway by inhibiting p65 activity},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202400952r}
}
EUVIMED